| Author/Editor | Jagodič, Klemen; Bizjak, Igor; Erklavec, Marko; Poteko, Sandi; Korošec, Helena; Kmetec, Andrej; Tršinar, Bojan | |
| Title | Quality of life in patients with prostate cancer treated with LH-RH agonists | |
| Type | članek | |
| Vol. and No. | Letnik 2, št. 1 | |
| Publication year | 2008 | |
| Volume | str. 30-35 | |
| Language | eng | |
| Abstract | The aim of the study was to identify factors that influence quality of life (Qol.) in patients with prostate carcinoma treated with luteinizing hormone-releasing hormone (LH-RH) agonists. Patients and methods: Patients treated with LH-RH agonists were administred QLQ-C30 and QLQ-PR25 questionnaires of the European Organization for Research and Treatment of Cancer. Additional parameters were evaluated: age, body mass index, prostate specific antigen, presence of metastases, previous retropubic radical prostatectomy, (RRP), previous radiotherapy, duration of treatment with LH-RH agonists, treatment with anti-androgens. Results: Fifty-eight patients before first LH-RH agonists application served as the control group. Eighty-five patients with subsequent application formed the study group. The patients in the control group had better global health status (p=0.000), physical function (p=0.002), erectile function (p=0.000) and sexual function (p=0.001), and less treatment related symptoms (p=0.000) than the patients in the study group. Patients with metastatic disease had worse global health status (p=0.040), physical function (p=0.002), role function (p=0.002) and social function (social function)(p=0.021), and were more fatigued (p=0.012) and suffered more pain (p=0.006) than patients without metastases. Patients with previous radiotherapy had worse gastrointestinal symptoms than the rest of the group (p=0.029). Gastrointestinal symptoms had reduced social function (p=0.000). Patients with previous RRP had worse erectile function (p=0.039) and were more incontinent (p=0.010) than the rest of the group. Incontinent patients had worse social function (p=0.045) and had more financial problems (p=0.033) than continent patients. There were no statistically significant differences in any parameters of Qol. between patients treated with triptorelin or goserelin. Conclusions: Treatment with LH-RH agonists reduces Qol. (Abstract truncated at 2000 characters) | |
| Descriptors | PROSTATIC NEOPLASMS GOSERELIN TRIPTORELIN QUALITY OF LIFE GOSERELIN TRIPTORELIN |